2006
MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer.
Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. The Yale Journal Of Biology And Medicine 2006, 79: 153-63. PMID: 17940625, PMCID: PMC1994803.Peer-Reviewed Original ResearchConceptsOvarian cancer cellsEpithelial ovarian cancerExpression of MyD88Ovarian cancerOverall survivalCancer cellsMyD88 expressionRecurrent epithelial ovarian cancerShorter progression-free intervalOvarian malignant tumorsPositive ovarian cancer cellsProgression-free intervalTime of surgeryPaclitaxel combination chemotherapySpecific tumor markersPure cancer cellsCytotoxic agent paclitaxelPaclitaxel chemoresistanceWestern blot analysisPaclitaxel chemotherapyClinical courseCombination chemotherapyAppropriate therapyProinflammatory cytokinesPoor response
2005
Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.
Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. American Journal Of Neuroradiology 2005, 26: 266-73. PMID: 15709123, PMCID: PMC7974081.Peer-Reviewed Original ResearchConceptsBlood volume measurementsDSC-MR imagingLow-grade oligodendrogliomasMR imagingWorld Health Organization grade II astrocytomaGrade II astrocytomasContrast-enhanced MR imagingCerebral blood volume measurementsLow-grade astrocytomasContrast-enhanced MRLow-grade gliomasSpecific tumor markersDynamic susceptibility contrast-enhanced MR imagingMaximum relative CBVDiagnosis of gliomaSurgical resectionConsecutive patientsHistologic confirmationHistologic subtypeCommon subtypeHistopathologic evaluationMorphologic aberrationsTumor vascularityTumor markersAnatomic imaging
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply